Fidaxomicin antibiotic (Dificid): Treatment for treatment of adults with Clostridium difficile-associated diarrhea
Formulary , 10/28/2011
On May 2011, FDA approved fidaxomicin for the treatment of adults with Clostridium difficile–associated diarrhea (CDAD). Fidaxomicin works by inhibiting RNA synthesis via RNA polymerases, and acts locally in the gastrointestinal tract to target C difficile with minimal systemic absorption. To prevent the development of drug–resistant bacteria, fidaxomicin should only be prescribed in the presence of proven or strongly suspected C difficile infection.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.